Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratoryReview Published on 2020-09-072022-10-29 Journal: Thrombosis Journal [Category] COVID-19, [키워드] activated affecting anticoagulation Coagulopathy Complexes Coronavirus disease 2019 COVID-19 D-dimer D-dimers effective extreme fibrinogen fibrinolysis fibrinolytic Guidance Hemostasis heparin incidence Inflammatory response Laboratory limitations management Prothrombin time question raising reliability reported thrombin Thrombin generation Thromboembolic event Thromboprophylaxis thrombosis thrombotic risk Treatment unfractionated heparin Viscoelastic tests with COVID-19 [DOI] 10.1186/s12959-020-00230-1 PMC 바로가기 [Article Type] Review
Elevated Plasmin(ogen) as a Common Risk Factor for COVID-19 SusceptibilityReview Published on 2020-07-012023-06-14 Journal: Physiological reviews [Category] MERS, SARS, [키워드] Comorbidity COVID-19 fibrinolysis plasmin(ogen) SARS-CoV-2 [DOI] 10.1152/physrev.00013.2020 PMC 바로가기 [Article Type] Review
Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysisCommentary Published on 2020-04-202022-10-29 Journal: World Journal of Emergency Surgery : WJES [Category] Coronavirus, SARS, [키워드] acute respiratory distress acute respiratory distress syndrome (ARDS) Analysis ARDS ARDS patients base COVID-19 COVID-19 pandemic COVID-19 patient criteria Critical care Critically ill Critically ill patient death defined demonstrated diagnosis of ARDS eligible fibrinolysis IMPROVE Markov Mild moderate Mortality pandemic PaO parameter Patient patient group patients pulmonary failure reduced reducing resource Result social distancing Standard therapy survival syndrome systemic tissue plasminogen activator Tissue plasminogen activator (tPA) transition transitioned USA was reduced [DOI] 10.1186/s13017-020-00305-4 PMC 바로가기 [Article Type] Commentary